Cost-effectiveness of continuing pneumococcal conjugate vaccination at age 65 in the context of indirect effects from the childhood immunization program.

CONCLUSION: Indirect effects from the childhood PCV13 program have dramatically increased the cost per QALY of continuing to recommend PCV13 at age 65 after only a few years. PMID: 31889609 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31889609?dopt=Abstract

Source: Vaccine - December 26, 2019 Category: Allergy & Immunology Authors: Stoecker C, Kobayashi M, Matanock A, Cho BH, Pilishvili T Tags: Vaccine Source Type: research